罗格列酮联合卡托普利治疗早期糖尿病肾病的疗效分析

摘要

Objective:To investigate the therapeutic efficacy of rosiglitazone combined with captopril in the treament of early-stage diabetic nephropathy (EDN). Methods:98 cases of EDN were divided into the control group (n=49) and the observation group (n=49). The control group received hypoglycemic therapy only, while the observation group was given rosiglitazone, captopril baesd on hypoglycemic therapy. Results:①Before treatment, there were no siginificant differences in the endogenous creatinine clearance rate(Ccr), 24h urinary albumin excretion rate(UAER), fasting blood glucose (FPG), glycated hemoglobin(HbA1c), Cystatin C (Cys C), diastolic blood pressure (DBP), systolic blood pressure (SBP) between the the control group and the observation group(P>0.05). After treatment, the UAER、FPG、HbA1c、Cys C、DBP and SBP of the observation group were siginificantly lower than those of the control group, respectively(P<0.05), while the Ccr was siginificantly higher(P<0.05). ②After evaluation, and the data showed that the therapeutic efficacy of the observation group was siginificantly better than that of the control group(P<0.05).③No obvious adverse reaction was found in the bservation group during the treatment. Conclusion:The rosiglitazone combined with captopril can obviously improve the reanl function in patiens with EDN.%目的：探讨罗格列酮联合卡托普利治疗早期糖尿病肾病(EDN)的疗效。方法：将98例EDN患者随机分为对照组(n=49)与观察组(n=49),对照组患者仅接受降血糖治疗,观察组患者在降血糖治疗基础上再联合使用罗格列酮、卡托普利。结果：①治疗前,两组患者的内生肌酐清除率(Ccr)、24h尿白蛋白排泄率(UAER)、空腹血糖(FPG)、糖化血红蛋白(HbA1c)、胱抑素C(Cys C)、舒张压(DBP)、收缩压(SBP)相比差异无统计学意义(P>0.05)。治疗后,观察组的UAER、FPG、HbA1c、Cys C、DBP、SBP显著低于对照组(P<0.05),Ccr显著高于对照组(P<0.05)。②经疗效评价,观察组的治疗效果显著优于对照组(Z=5.972,P<0.05)。③治疗过程中,观察组患者均未见明显的不良反应。结论：罗格列酮联合卡托普利可显著改善EDN患者的肾功能。